$50.19
+1.04 (+2.12%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AXGN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 3 observational · 3 with posted results
Held by 14 tracked-famous managers (CITADEL ADVISORS LLC, Holocene Advisors, LP, First Eagle Investment Management, LLC, TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, +9 more) · FINRA short interest 3.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve ReconstructionNCT07657182Recovery of motor functionRandomized · Single-masked · Treatment | Phase 4 | Recruiting | Biological: Avance Nerve Graft · Procedure: Sural nerve autograft | Peripheral Nerve Injury, Peripheral Nerve Discontinuity, Mixed Peripheral Nerve Injury, Motor Peripheral Nerve Injury, Upper Extremity Nerve Injury | 178 | 2030-12-05 | in 1,569 d | 2026-06-18 |
| Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve ReconstructionNCT01526681observationalAvance Nerve Graft: Incidence of Avance Nerve Graft Related Adverse Events | — | Active, not recruiting | Other: Processed Human Nerve Graft, Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc., Autogenous Nerve Graft · Device: Nerve Tube Conduit · Procedure: Autologous Breast Reconstruction with Neurotization, Autologous Breast Reconstruction without Neurotization | Peripheral Nerve Injuries | 3,126 | Nov 2028 | ≤ 834 d | 2026-01-26 |
| Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve EndsNCT04865679Safety: Adverse Events (AEs), Serious Adverse Events (SAEs), or Unanticipated Adverse Device Effects (UADEs)Open-label · Treatment | Not applicable | Active, not recruiting | Device: Axoguard Nerve Cap® | Symptomatic Neuroma, Amputation, Chronic Nerve Pain | 15 | Dec 2026 | ≤ 134 d | 2026-06-03 |
| Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome DecompressionNCT06117501Visual analog scale (VAS)Open-label · Treatment | Not applicable | Active, not recruiting | Device: Axoguard HA+ Nerve Protector™ | Recurrent Cubital Tunnel Syndrome, Recalcitrant Cubital Tunnel Syndrome | 20 | Dec 2026 | ≤ 134 d | 2025-10-07 |
| Surgical Treatment of Chronic Neuropathic PainNCT04287075observationalPerformance: Change in Visual Analog Scale (VAS) for Pain Score at 1 year in both the surgery and non-surgery cohorts | — | Terminatedsponsor's stated reason: The study was terminated due to lower than expected enrollment. The decision to terminate the study was not based on any safety or efficacy concerns. | Procedure: Surgical Management of Neuroma | Chronic Neuropathic Pain | 8 | 2024-01-24actual | — | 2024-03-26 |
| Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma PainNCT03940963results2025-01-09Change in Visual Analog Scale (VAS) For Pain Score at 12 Post-operative Months in Comparative Phase SubjectsRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: AxoGuard® Nerve Cap · Procedure: Standard Neurectomy | Symptomatic Neuroma, Morton's Neuroma, Chronic Nerve Pain | 86 | 2023-07-17actual | — | 2025-01-09 |
| Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve RepairNCT01809002results2023-07-12Static Two-Point Discrimination (Pre-defined Mixed Modeling Approach)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Processed Nerve Allograft (human) · Device: Collagen Nerve Cuff | Peripheral Nerve Discontinuities | 220 | 2021-08-30actual | — | 2023-07-12 |
| Registry of Avive® Soft Tissue Membrane Utilization in Selected Applications of Acute Trauma of the Upper ExtremityNCT03943134observationalChanges in QuickDASH (Disabilities of Arm, Shoulder, Hand) score at 2,4,8,12,16,24, and 52 post-operative weeks (Adult subjects only). | — | Terminatedsponsor's stated reason: Axogen suspended market availability of the Avive® Soft Tissue Membrane effective June 1, 2021. This decision was not related to any safety concerns or product quality issues. | Other: Minimally Processed Human Umbilical Cord Membrane, Standard Surgical Procedures | Acute Upper Extremity Trauma | 7 | 2020-12-17actual | — | 2025-08-20 |
| Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate CancerNCT00953277Surgeon Assessment of Technical FeasibilityOpen-label · Treatment | Phase 4 | Completed | Other: Processed Human Nerve Tissue Scaffold | Peripheral Nerve Injury, Prostate Cancer, Radical Prostatectomy, Nerve Reconstruction, Cavernous Nerve Injury | 12 | Apr 2015actual | — | 2024-08-12 |
| A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair OptionsNCT00948025results2020-12-01Recovery of Static 2-point Discrimination in the Affected DigitRandomized · Double-masked · Treatment | Not applicable | Terminatedsponsor's stated reason: transitioning from 361 HCT/P Tissue to a Biologic (BLA) | Device: Hollow tube nerve conduit, synthetic or biosynthetic · Other: Processed Human Nerve Tissue | Traumatic Nerve Injury | 23 | Dec 2014actual | — | 2020-12-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19